» Articles » PMID: 11239468

NF-kappaB-inducing Kinase Regulates the Processing of NF-kappaB2 P100

Overview
Journal Mol Cell
Publisher Cell Press
Specialty Cell Biology
Date 2001 Mar 10
PMID 11239468
Citations 405
Authors
Affiliations
Soon will be listed here.
Abstract

Processing of the nf(kappa)b2 gene product p100 to generate p52 is an important step in NF-kappaB regulation. We show that this step is negatively regulated by a processing-inhibitory domain (PID) within p100 and positively regulated by the NF-kappaB-inducing kinase (NIK). While the PID suppresses the constitutive processing of p100, NIK induces p100 processing by stimulating site-specific phosphorylation and ubiquitination of this precursor protein. Further, a natural mutation of the gene encoding NIK in alymphoplasia (aly) mice cripples the function of NIK in p100 processing, causing a severe defect in p52 production. These data suggest that NIK is a specific kinase regulating p100 processing and explain why the aly and nf(kappa)b2 knockout mice exhibit similar immune deficiencies.

Citing Articles

CD109, a master regulator of inflammatory responses.

Batal A, Garousi S, Finnson K, Philip A Front Immunol. 2025; 15:1505008.

PMID: 39990858 PMC: 11842317. DOI: 10.3389/fimmu.2024.1505008.


NF-κB-Inducing Kinase Is Essential for Effective c-Rel Transactivation and Binding to the Promoter in Macrophages.

Cuesta N, Staniszewska A, Moreno C, Punzon C, Fresno M Biology (Basel). 2025; 14(1).

PMID: 39857264 PMC: 11760456. DOI: 10.3390/biology14010033.


Gut instinct: harnessing the power of probiotics to tame pathogenic signaling pathways in ulcerative colitis.

Hsu C, Mustafa M, Omar T, Taher S, Ubaid M, Gilmanova N Front Med (Lausanne). 2024; 11:1396789.

PMID: 39323474 PMC: 11422783. DOI: 10.3389/fmed.2024.1396789.


NFκB signalling in colorectal cancer: Examining the central dogma of IKKα and IKKβ signalling.

McKenzie M, Lian G, Pennel K, Quinn J, Jamieson N, Edwards J Heliyon. 2024; 10(12):e32904.

PMID: 38975078 PMC: 11226910. DOI: 10.1016/j.heliyon.2024.e32904.


: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity.

Medeiros M, Guenka S, Bastos D, Oliveira K, Brassesco M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931401 PMC: 11206879. DOI: 10.3390/ph17060734.